SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX
Clinical trials for SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX explained in plain language.
Never miss a new study
Get alerted when new SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX trials appear
Sign up with your email to follow new studies for SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Double-Drug attack shows promise for tough head and neck cancers
Disease control CompletedThis study tested whether combining two FDA-approved cancer drugs, cetuximab and nivolumab, could help people with advanced head and neck cancer that has returned or spread. A total of 95 participants received the drug combination to find the best dose and see if it improves surv…
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX
Phase: PHASE1, PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Can less radiation be safer without sacrificing cancer control?
Disease control CompletedThis study tested whether giving lower doses of radiation after surgery for head and neck cancer could reduce long-term side effects like dry mouth and trouble swallowing, while still keeping the cancer from coming back. About 200 patients with certain stages of oral, throat, or …
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX
Phase: PHASE2 • Sponsor: University of Erlangen-Nürnberg Medical School • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
AI shrinks radiation target, cuts side effects in head and neck cancer
Disease control CompletedThis study tested a new way to give radiation for head and neck cancer. Instead of treating the whole neck, doctors used artificial intelligence to focus radiation only on the cancer spots. 67 patients took part to see if this approach could reduce side effects without increasing…
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX
Phase: PHASE2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New combo therapy aims to stop head and neck cancer return
Disease control CompletedThis phase II trial tested whether adding the targeted drug cetuximab to standard chemotherapy and radiation could help prevent head and neck cancer from coming back after surgery. The study enrolled 53 patients with certain high-risk features. The main goal was to see how many p…
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX
Phase: PHASE2 • Sponsor: Centre Antoine Lacassagne • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Smart radiotherapy aims to spare saliva glands in head and neck cancer patients
Symptom relief CompletedThis study tested a new type of radiation therapy that adjusts the treatment beam each day based on the patient's current anatomy. The goal was to see if this daily adaptive approach could reduce chronic dry mouth (xerostomia) compared to standard radiation in 50 people with head…
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX
Phase: PHASE2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 11:03 UTC
-
Can MRI measurements be trusted for head and neck cancer?
Knowledge-focused CompletedThis study looked at how repeatable and reproducible ADC maps are for measuring head and neck cancer in 58 adults. Participants had MRI scans using a standard method to see if results were consistent across different machines and sessions. The goal was to improve the reliability …
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX
Sponsor: Regina Elena Cancer Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:03 UTC
-
Study tracks swallowing troubles in head and neck cancer patients for 18 months
Knowledge-focused CompletedThis study followed 240 people with head and neck cancer to see how their swallowing changed from diagnosis to 18 months after their first treatment. Researchers used a questionnaire called the Deglutition Handicap Index (DHI) to measure patients' own experience of swallowing pro…
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX
Sponsor: Centre Antoine Lacassagne • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC